Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 3, 2026
- First Tracks Biotherapeutics said ANB033 achieved statistically significant protection against gluten-induced intestinal damage and symptoms in a celiac disease Phase 1b cohort. It also completed a $200 million private placement, resulting in $343 million pro forma cash.
- 10-Q report · filed Nov 3, 2026
- First Tracks Biotherapeutics said ANB033’s Phase 1b celiac Cohort 1 met histologic and symptom endpoints, with placebo-adjusted Vh:Cd improvement of +0.49 (p=0.009) and IEL reduction of -20.03 (p<0.001). Cash and cash equivalents totaled $155.6 million as of September 30, 2026.
The audio replay and transcript follow the call.